Dysgeusia - the distortion of taste - affects between 45 and 84 percent of cancer patients on active treatment.
Dysgeusia is one of the most under-discussed major side effects of chemotherapy. Prevalence estimates in the literature range from 45 percent to 84 percent of patients on active treatment 2. That seven-fold range is itself revealing: it reflects how differently dysgeusia presents across drug classes, treatment regimens, and patient populations - not noise in the data.
The standard instrument for measuring it is the CiTAS scale (Chemotherapy-induced Taste Alteration Scale) 3: eighteen items, five-point Likert, three dimensions covering quantitative changes in flavor perception (hypogeusia, ageusia), qualitative changes (heterogeusia, cacogeusia), and nutrition-related effects 4. CiTAS is the closest the field has to a shared vocabulary, and it is what §05 of this deliverable uses to map symptom profiles to formulation strategies.
Dysgeusia in cancer patients on active treatment is not a single failure mode. Four mechanistically distinct injuries co-occur during chemotherapy, each contributing independently to the overall taste disturbance. Understanding all four is essential - because a gum that only addresses one will miss the majority of what a patient is experiencing.
Mechanism 01
Chemo kills taste bud cells faster than the body can replace them. Fewer functional receptors means weaker signals - or none at all. Salt is the hardest-hit taste and the slowest to come back. 5 10
SuzChews answer: sour / tart stimulation, which stays perceptible even under receptor lossMechanism 02
Treatment changes the pH, protein makeup, and buffering of saliva - the fluid that carries flavor to receptors. Flow rate doesn't matter; the chemistry does. More saliva doesn't fix it. 6
SuzChews answer: sustained chewing that stimulates saliva production while delivering active ingredientsMechanism 03
Platinum drugs and iron compounds bind directly to tongue receptors and produce a persistent metallic taste. It's not from the food - it's happening at the receptor itself, before flavor even registers. 7
SuzChews answer: trigeminal stimulation (separate nerve, unaffected) + umami bitter masker at the receptorMechanism 04
Platinum agents oxidize cell membranes in the mouth, releasing carbonyl compounds that generate bitter and rancid signals on their own. Sweet candy doesn't help because the bad signal is being produced internally - independently of whatever the patient is eating. 8
SuzChews answer: umami peptides compete at the same receptor sites + trigeminal redirectFifth mechanism - outside scope
A fifth contributor - peripheral and central neuropathy blocking cranial-nerve taste transmission - appears in some regimens 9. This pathway is outside the reach of a topical oral intervention. SuzChews explicitly acknowledges this limit in §04.4 and the algorithm does not attempt to address it.
The clinical implication of Fig. 02.1 is that dysgeusia has a well-bounded intervention window. Symptoms emerge predictably after first exposure, escalate over weeks, and recover slowly post-treatment. Any intervention designed to address the experience - rather than the underlying disease - needs to be (a) deployable within days of first exposure, (b) tolerable across weeks-to-months, and (c) usable through the long tail of post-treatment recovery.
That requirement set excludes most pharmacological options (which add burden to an already over-medicated patient) and most dietary modifications (which patients lack the energy to maintain). It strongly favors a passive, palatable, mouth-resident intervention - which is the design thesis behind SuzChews.
The seven-fold prevalence range from §02.1 is the first hint that dysgeusia is not one disorder - it is a family of presentations. Two patients on the same regimen at the same week of treatment can describe wildly different experiences: one tastes everything as bitter, one loses salt entirely, one experiences metallic intensity that fluctuates by hour.
That variability has consequences for any intervention strategy. An aggregate "dysgeusia gum" that targets the average patient will work for some and fail for many. The right design is one that decomposes the symptom space, identifies which mechanisms are dominant for a given patient, and recommends an ingredient mix matched to that patient. That decomposition is what §05 builds. The simulation in §06 lets a reader experience the variability directly.
Who this is for
SuzChews is designed specifically for cancer patients experiencing chemotherapy-induced dysgeusia. Not a general wellness product. Not a dry-mouth remedy. For patients who have lost the ability to taste normally because of active treatment - and for whom that loss is compounding an already difficult recovery.
Variables explored and ruled out
Two candidate variables - generic taste-altering disease history (unrelated comorbidities like reflux, diabetes) and chronological age in isolation - were considered and dropped from the algorithm in §05. Disease history was uncorrelated with dysgeusia severity in the literature once treatment regimen was controlled for 11; age was correlated with severity but the mechanism is mediated entirely through taste-bud-fragility, which is captured by the recovery-time variable in §05. Including both would have inflated dimensionality without adding signal.
Existing strategies for managing chemotherapy-induced dysgeusia fall into three buckets, none of which fit the requirement set developed above.
Dietary modification (use plastic utensils, marinate proteins, cold over hot food) places ongoing cognitive and physical load on a patient already operating below baseline. Pharmacological supplementation (zinc gluconate, glutamine, lactoferrin) has weak and inconsistent evidence and adds to medication burden. General-purpose candy and lozenges are convenient and palatable but were designed for halitosis or dry mouth, not for dysgeusia - they do not target the mechanisms in §02.2 and they do not address the salt-perception loss that defines post-treatment recovery.
SuzChews fills that gap. A chewing gum is mouth-resident, continuously stimulating, requires no behavioral change, and can be formulated to target the four reachable mechanisms simultaneously. The remainder of this site - §03 through §06 - documents what that gum is, how it was designed, and what the evidence and methodology behind it look like.